During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

A groundbreaking multinational clinical trial, named RESILIENCE, is underway to test a promising new treatment aimed at ...

Chemotherapy seeks to destroy tumor cells and has been a standard treatment for cancer for decades. However, it doesn't ...

Once the biomarkers were developed, the CNIO team tested them in an innovative way: with a simulated trial, that is, with ...

New DNA test predicts chemotherapy resistance before treatment, potentially sparing patients from ineffective toxic drugs.

Chronic kidney disease (CKD) and hypertension are common health problems among childhood cancer survivors with potentially life-threatening sequelae.

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than ...

A new genomic test has been developed to accurately predict whether a patient’s cancer will resist common chemotherapy ...

The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested in a Phase II clinical trial to see if it can help cancer patients treated with common ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

As part of the segment, Walter Klemp, Founder, President, CEO and Chairman of Moleculin, discussed the Company's recently announced positive FDA feedback received on the Pediatric Study Plan for ...